Cepheid Reports 2009 Second Quart...(--- Net cash provided by financin...),Health

Date:7/30/2009

--- Net cash provided by financing activities 2,343 9,329 ----- ----- Effect of exchange rate change on cash 112 17 --- -- Net increase in cash and cash equivalents 1,248 8,390 Cash and cash equivalents at beginning of period 23,478 16,476 ------ ------ Cash and cash equivalents at end of period $24,726 $24,866 ======= ======= (1) See discussion in press release.

                                     CEPHEID

                    RECONCILIATION OF GAAP TO NON-GAAP MEASURES
                       (in thousands, except per share data)


                                   Three Months Ended    Six Months Ended
                                         June 30,           June 30,
                                      --------------      --------------
                                      2009      2008      2009      2008
                                      ----      ----      ----      ----
                                                As                   As
                                             Restated (1)         Restated (1)
    Total Product Sales              $39,560   $38,953   $76,148   $80,873
    Total Revenues                   $41,021   $42,050   $79,788   $86,883

    Cost of product sales            $23,250   $23,039   $43,940   $46,193
      Stock compensation expense        (728)     (247)   (1,082)     (597)
      Amortization of purchased
       intangible assets                (324)     (241)     (648)     (482)
                                     -------   -------   -------   -------
    No
'/>"/>
SOURCE  Cepheid
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results